Sir -We believe, like Drs Gold and Osband, that application of CD45RO+CD4+ helper/killer cells to adoptive immunotherapy has many advantages for the potentiation of host antitumour immunity. In previous papers (Nishimura et al., 1991; 1992a,b; Nakamura et al., 1992) we initially developed a large-scale culture system of pure human CR45RO+CD4+ T cells. We intend to use these CD4+ T cells for new trials of adoptive immunotherapy, termed 'helper/killer therapy', in combination with other kinds of killer cells (CD8+T or 76T) and bispecific antibody (BSAb). Recent results have demonstrated that introduction of local help by gene technology resulted in the rejection of tumour cells of low immunogenicity (Fearon et al., 1990) . Therefore, we believe that the targeting of both CD4+ helper T cells and CD8+ T cells using BSAb may facilitate the activation of antitumour immunity at the local site of a tumour.
In the letter from Drs Gold and Osband, they claim that their developed autolymphocyte therapy (ALT) is adoptive tumour immunotherapy based upon the infusion of CD4+ CD45RO+ T cells activated with OKT3 and OKT3-stimulated conditioned medium (T3CS). However, we cannot find any evidence that they used CD4+CD45RO+ enriched T cell populations for ALT. As described in their own paper (Osband et al., 1990) , the cells used for ALT consisted of 49.6% T cells and 51.4% other non-T cell populations. T cells consisted of 45.6% CD4+ T cells and 18.4% CD8+ T cells. Furthermore, activation of peripheral blood lymphocytes, which contained 26.7% CD4+CD45RO+2H4-T cells, with OKT3 mAb and T3CS did not cause preferential growth of the CD4+CD45RO+ (2H4-) T cell population (24.2%). As described in their basic study (Celis et al., 1991) and other results (Panzer et al., 1990) , it was demonstrated that the activation of purified CD4+ T cells with IL-1 or IL-1 containing T3CS resulted in the preferential growth of CD4+ CD45RO+ T cells. Therefore, the activation of isolated CD4+ T cells with OKT3 mAb plus T3CS may improve the yield of CD4+CD45RO+ T cells and may therefore confer benefits for the therapeutic effect of ALT. In summary, our answer to their first question is that we can agree the working hypothesis of ALT using CD4+CD45RO+ T cells, but we cannot find any evidence from their data that unseparated PBL are sufficient to induce preferential growth of CD4+ CD45RO+ T cells useful for adoptive tumour immunotherapy.
It is very interesting results that a certain threshold dose of infused lymphocytes was critical for the therapeutic effect of adoptive immunotherapy (Ross & Osband, 1989) . They claim that the suppressive effect of a large number of cells (12-15 x 106 cells/KG/infusion) might be derived from the CD4+CD45RO+ T cells which may cause an 'anti-idiotypic' reaction with concomitant generation of suppressor cells. This might be true if they use pure CD4+CD45RO+ T cells for ALT. As described above, however, they used heterogeneous cell population which contained only 24.6% CD4+ CD45RO+ T cells. Therefore, it is not necessary to speculate that infusion of a large number of CD4+ T cells might suppress antitumour activity. They cannot exclude the possibility that classical CD8+ suppressor T cells showed in vivo suppressive activity. Nevertheless, their results provide important information concerning the number of cells used for adoptive immunotherapy. The aims of ALT and helper/ killer therapy seem to be different. The aim of the former is a potentiation of host antitumour immunity by systemic adoptive transfer. The aim of the latter is the targeting of CD4+ T cells and CD8 + T cells into the tumour tissues via the tumour-feeding artery in combination with BSAb. In the case of systemic administration, a small number of CD4+ T cells might be sufficient for immunoregulatory action in vivo. In contrast, large numbers of CD4+ T cells with CD8+ killer T cells may be necessary for BSAb-dependent induction of IL-2 production and tumour eradication at the local sites because tumour cells produce immunosuppressive factors.
In conclusion, we believe that separation of CD4+ T cells from PBL before culture is essential for selective growth of CD4+CD45RO+ T cells and that a large number of CD4+ T cells may be necessary for the augmentation of local effects at local sites of tumour involvement. We hope that Drs Gold and Osband will demonstrate improved therapeutic effects of ALT using controlled pure CD4+ and CD8+ T cell popula-
